Analgesics in
Country Report
Executive Summary
Oct 2019PROSPECTS
Government aims to encourage greater self-care amongst Dutch population with new policy
Traditionally, the Dutch have shown greater restraint over the use of medication, which had translated into less frequent use of self-medication products compared to other European countries. However, concerned about the increasing demand for healthcare in the country and in an attempt to limit costs on the healthcare system with local consumers who do require basic medication often turning to their doctors for a prescription, the Dutch government implemented a new policy on 1 January 2019.
Increasing demand for topical analgesics through directly targeting of painful area
Despite growing from a low sales base, there was notable increasing demand for topical analgesics/anaesthetic in 2019, a trend that is predicted to continue into the forecast period, as some consumers continue to choose to move away from oral medicine in favour of directly targeting certain areas of pain that are deemed to be better treated with topical products. This trend is being supported by major players in the category, with leading brands such as Voltaren OTC Emulgel 1.
Potential for greater segmentation by brands in terms of targeting specific types of pain
In addition to targeting muscle pain through topical analgesics and the opportunity this category holds for other brands to enter, there is still potential for players to look to differentiate their products through types of pain as a key area of focus to drive value sales of analgesics over the forecast period. Analgesics that specifically target, for instance, females who suffer from menstruation pain, is likely to be more notable amongst branded products such as Aleve Feminax than private label, supported by larger parent companies that are able to invest in and develop more complex products, in addition to enjoying higher marketing budgets.
COMPETITIVE LANDSCAPE
GSK Consumer Healthcare gains leadership of analgesics through joint venture with Pfizer
GSK Consumer Healthcare gained leadership of overall analgesics in 2019 from Bayer Consumer Care following a joint venture between GlaxoSmithKline Plc with Pfizer Inc in 2018. This has resulted in GSK Consumer Healthcare distributing Pfizer’s analgesics ibuprofen brand Advil, which is also present in topical analgesics/anaesthetic with Advil Gel leading to strong share gain for the formerly second-ranked player.
Despite share loss, Bayer retains leadership of systemic analgesics
Despite losing some value share after falling to second position behind GSK Consumer Healthcare, Bayer Consumer Care BV continues to be a strong player, retaining its leadership of both adult and paediatric analgesics. The company offers an expansive product portfolio, dominating aspirin with its widely recognised brands Aspirine, although declining demand for adult aspirin has led it to place its focus on more demanded areas such as adult acetaminophen with its Finimal brand, and strengthening its leadership of paediatric acetaminophen with Sinaspril Paracetamol due to the growing demand for paediatric analgesics.
Private label retains strong value share of analgesics
Private label continued to hold strong value share within analgesics in 2019, which is particularly strong in adult acetaminophen, although it lost some sales to branded products in this category, while gaining ground in paediatric acetaminophen as parents began to gain greater trust in retailers’ own analgesics offers. This has led to greater share gain and strong value growth through modern grocery retailers such as hypermarkets and supermarkets.
Your Recently Viewed Reports
Analgesics in the Netherlands
Samples (FAQs about samples):
Delivery: Files are delivered directly into your account within a few minutes of purchase.
Overview
Discover the latest market trends and uncover sources of future market growth for the Analgesics industry in Netherlands with research from Euromonitor's team of in-country analysts.
Find hidden opportunities in the most current research data available, understand competitive threats with our detailed market analysis, and plan your corporate strategy with our expert qualitative analysis and growth projections.
If you're in the Analgesics industry in Netherlands, our research will save you time and money while empowering you to make informed, profitable decisions.
The Analgesics in Netherlands market research report includes:
- Analysis of key supply-side and demand trends
- Detailed segmentation of international and local products
- Historic volumes and values, company and brand market shares
- Five year forecasts of market trends and market growth
- Robust and transparent market research methodology, conducted in-country
Our market research reports answer questions such as:
- What is the market size of Analgesics in Netherlands?
- What are the major brands in Netherlands?
- Are combination products with acetaminophen still popular?
Why buy this report?
- Gain competitive intelligence about market leaders
- Track key industry trends, opportunities and threats
- Inform your marketing, brand, strategy and market development, sales and supply functions
This industry report originates from Passport, our Consumer Health market research database.
Analgesics in the Netherlands - Category analysis
HEADLINES
PROSPECTS
Government aims to encourage greater self-care amongst Dutch population with new policy
Increasing demand for topical analgesics through directly targeting of painful area
Potential for greater segmentation by brands in terms of targeting specific types of pain
COMPETITIVE LANDSCAPE
GSK Consumer Healthcare gains leadership of analgesics through joint venture with Pfizer
Despite share loss, Bayer retains leadership of systemic analgesics
Private label retains strong value share of analgesics
CATEGORY DATA
Table 1 Sales of Analgesics by Category: Value 2014-2019Table 2 Sales of Analgesics by Category: % Value Growth 2014-2019
Table 3 NBO Company Shares of Analgesics: % Value 2015-2019
Table 4 LBN Brand Shares of Analgesics: % Value 2016-2019
Table 5 Forecast Sales of Analgesics by Category: Value 2019-2024
Table 6 Forecast Sales of Analgesics by Category: % Value Growth 2019-2024
Consumer Health in the Netherlands - Industry Overview
EXECUTIVE SUMMARY
Rising disposable incomes and higher VAT leads to stable current value growth for consumer health
Some products removed from basic health insurance as government encourages self-care amongst local population
GSK Consumer Healthcare takes over leadership of consumer health, now representing former Pfizer brands
Internet retailing continues to rapidly gain share supported by increasing popularity of online players
Marginally stronger value performance predicted for consumer health
MARKET INDICATORS
Table 7 Consumer Expenditure on Health Goods and Medical Services: Value 2014-2019Table 8 Life Expectancy at Birth 2014-2019
MARKET DATA
Table 9 Sales of Consumer Health by Category: Value 2014-2019Table 10 Sales of Consumer Health by Category: % Value Growth 2014-2019
Table 11 NBO Company Shares of Consumer Health: % Value 2015-2019
Table 12 LBN Brand Shares of Consumer Health: % Value 2016-2019
Table 13 Penetration of Private Label in Consumer Health by Category: % Value 2014-2019
Table 14 Distribution of Consumer Health by Format: % Value 2014-2019
Table 15 Distribution of Consumer Health by Format and Category: % Value 2019
Table 16 Forecast Sales of Consumer Health by Category: Value 2019-2024
Table 17 Forecast Sales of Consumer Health by Category: % Value Growth 2019-2024
APPENDIX
OTC registration and classification
Vitamins and dietary supplements registration and classification
Self-medication/self-care and preventive medicine
Switches
Summary 1 OTC: Switches 2018-2019DEFINITIONS
SOURCES
Summary 2 Research SourcesRelated Reports
- Bayer in Consumer Health | Nov 2019
- Johnson & Johnson in Consumer Health | Nov 2019
- Consumer Health in Taiwan | Oct 2019
- Vitamins and Dietary Supplements in Latin America | Oct 2019
- Digestive Remedies in Western Europe | Oct 2019